CN1321628C - 湿磨方法 - Google Patents

湿磨方法 Download PDF

Info

Publication number
CN1321628C
CN1321628C CNB018119328A CN01811932A CN1321628C CN 1321628 C CN1321628 C CN 1321628C CN B018119328 A CNB018119328 A CN B018119328A CN 01811932 A CN01811932 A CN 01811932A CN 1321628 C CN1321628 C CN 1321628C
Authority
CN
China
Prior art keywords
grinding
drug substance
ppm
nylon
contamination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018119328A
Other languages
English (en)
Chinese (zh)
Other versions
CN1438876A (zh
Inventor
西蒙·J·霍兰
温迪·A·奈特
格雷厄姆·S·伦纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015856A external-priority patent/GB0015856D0/en
Priority claimed from GB0112496A external-priority patent/GB0112496D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1438876A publication Critical patent/CN1438876A/zh
Application granted granted Critical
Publication of CN1321628C publication Critical patent/CN1321628C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/16—Mills in which a fixed container houses stirring means tumbling the charge
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/16—Mills in which a fixed container houses stirring means tumbling the charge
    • B02C17/163—Stirring means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/22—Lining for containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Grinding-Machine Dressing And Accessory Apparatuses (AREA)
  • Disintegrating Or Milling (AREA)
CNB018119328A 2000-06-28 2001-06-22 湿磨方法 Expired - Fee Related CN1321628C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0015856.8 2000-06-28
GB0015856A GB0015856D0 (en) 2000-06-28 2000-06-28 Wet milling process
GB0112496A GB0112496D0 (en) 2001-05-22 2001-05-22 Wet milling process
GB0112496.5 2001-05-22

Publications (2)

Publication Number Publication Date
CN1438876A CN1438876A (zh) 2003-08-27
CN1321628C true CN1321628C (zh) 2007-06-20

Family

ID=26244560

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018119328A Expired - Fee Related CN1321628C (zh) 2000-06-28 2001-06-22 湿磨方法

Country Status (24)

Country Link
US (2) US20040089753A1 (cs)
EP (1) EP1294358B1 (cs)
JP (1) JP4188078B2 (cs)
KR (1) KR100786927B1 (cs)
CN (1) CN1321628C (cs)
AR (1) AR029284A1 (cs)
AT (1) ATE273695T1 (cs)
AU (2) AU2002215608B2 (cs)
BR (1) BR0111747A (cs)
CA (1) CA2413330A1 (cs)
CZ (1) CZ303572B6 (cs)
DE (1) DE60105023T2 (cs)
ES (1) ES2225624T3 (cs)
HU (1) HU230396B1 (cs)
IL (2) IL153231A0 (cs)
MX (1) MXPA03000051A (cs)
MY (1) MY128806A (cs)
NO (1) NO333747B1 (cs)
NZ (1) NZ522783A (cs)
PL (1) PL202623B1 (cs)
PT (1) PT1294358E (cs)
SI (1) SI1294358T1 (cs)
TW (1) TWI290836B (cs)
WO (1) WO2002000196A2 (cs)

Families Citing this family (355)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9619301A (en) * 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
GB0112497D0 (en) * 2001-05-22 2001-07-11 Smithkline Beecham Plc Formulation
GB0206200D0 (en) * 2002-03-15 2002-05-01 Glaxo Group Ltd Pharmaceutical compositions
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US7140567B1 (en) * 2003-03-11 2006-11-28 Primet Precision Materials, Inc. Multi-carbide material manufacture and use as grinding media
ES2329044T3 (es) 2003-06-17 2009-11-20 Phibrowood Llc Conservante para madera particulado y procedimiento para su produccion.
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
ATE450535T1 (de) 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
US7578455B2 (en) * 2004-08-09 2009-08-25 General Motors Corporation Method of grinding particulate material
US20060112850A1 (en) 2004-10-14 2006-06-01 Jun Zhang Micronized wood preservative formulations in organic carriers
EP1839502A4 (en) * 2004-12-07 2010-03-24 Ajinomoto Kk FINE AMINO ACID POWDER AND SUSPENSION THEREOF
US8703099B2 (en) 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
MY153424A (en) 2005-05-10 2015-02-13 Incyte Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2006120541A1 (en) 2005-05-10 2006-11-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Ether linked macrolides useful for the treatment of microbial infections
WO2007038215A1 (en) 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
KR101324737B1 (ko) 2005-12-13 2013-11-05 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
DE102006028590A1 (de) * 2006-06-22 2007-12-27 Forschungszentrum Karlsruhe Gmbh Vorrichtung und Verfahren zur Herstellung keramischer Granulate
CA2656039A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
AU2007260852B2 (en) 2006-06-23 2013-01-10 Incyte Corporation Purinone derivatives as HM74a agonists
US7828543B2 (en) * 2006-07-27 2010-11-09 Casa Herrera, Inc. Dough sheeter cutter roller
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US20080207731A1 (en) 2006-08-23 2008-08-28 Intellect Neurosciences, Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US7883039B2 (en) * 2007-02-27 2011-02-08 Collette Nv Continuous granulating and drying apparatus including measurement units
JP2008235481A (ja) * 2007-03-19 2008-10-02 Nippon Chem Ind Co Ltd 半導体ウエハ研磨用組成物、その製造方法、及び研磨加工方法
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
SI2173752T2 (sl) 2007-06-13 2022-09-30 Incyte Holdings Corporation Soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4- il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
DK2178858T3 (da) 2007-08-02 2012-03-19 Recordati Ireland Ltd Nye heterocycliske forbindelser som mGlu5-antagonister
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CN103936743B (zh) 2008-05-21 2018-04-24 因西特控股公司 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法
KR102031538B1 (ko) 2008-07-08 2019-11-08 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
WO2010077839A1 (en) 2008-12-15 2010-07-08 Wyeth Llc (Formerly Known As Wyeth) Substituted oxindol cb2 agonists for pain treatment
WO2010090680A1 (en) 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists
WO2010075270A1 (en) 2008-12-22 2010-07-01 Incyte Corporation 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators
CN102348718B (zh) 2009-01-14 2015-06-03 诺瓦克塔生物系统有限公司 去氧阿肽加定衍生物
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JPWO2010087447A1 (ja) * 2009-01-30 2012-08-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 微粉砕医薬組成物
CN102388060B (zh) 2009-02-04 2014-09-10 诺瓦克塔生物系统有限公司 阿肽加定衍生物
US20100317630A1 (en) 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
EP2396004A4 (en) 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
WO2010108059A1 (en) 2009-03-20 2010-09-23 Incyte Corporation Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor
US20100286186A1 (en) 2009-04-02 2010-11-11 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
RS59632B1 (sr) 2009-05-22 2020-01-31 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
WO2010149760A2 (en) 2009-06-24 2010-12-29 Shire Llc Mexiletine amino acid and peptide prodrugs and uses thereof
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
KR20120060203A (ko) 2009-07-17 2012-06-11 엘엘씨 샤이어 신규한 오피오이드의 카바메이트 아미노산과 펩티드 프로드럭 및 그의 용도
CN102625700A (zh) 2009-07-23 2012-08-01 夏尔有限责任公司 加兰他敏氨基酸和肽前药及其用途
EP2467362A4 (en) 2009-08-17 2013-06-26 Brigham & Womens Hospital Phosphatidylcholine TRANSFER PROTEIN INHIBITORS
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20120028931A1 (en) 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
GB0916163D0 (en) 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
US20120309676A1 (en) 2010-02-02 2012-12-06 Sjoerd Nicolaas Wadman Lantibiotic Salts
EP2536729A1 (en) 2010-02-18 2012-12-26 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
HRP20160326T1 (hr) 2010-03-10 2016-05-20 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kao inhibitori jak1
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
PL2574168T3 (pl) 2010-05-21 2016-10-31 Preparaty inhibitora kinazy janusowej do stosowania miejscowego
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2590985B1 (en) 2010-07-09 2014-05-14 Recordati Ireland Limited Novel spiroheterocyclic compounds as mglu5 antagonists
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
NZ607000A (en) 2010-08-24 2015-02-27 Imp Innovations Ltd Glycodendrimers of polypropyletherimine
EP2611772B1 (en) 2010-09-02 2014-09-24 GlaxoSmithKline Intellectual Property Development Limited 2-(benzyloxy)benzamides as lrrk2 kinase inhibitors
CA2812029A1 (en) 2010-09-15 2012-03-22 Shire Llc Prodrugs of guanfacine
WO2012046062A1 (en) 2010-10-05 2012-04-12 Shire, Llc Use of prodrugs to avoid gi mediated adverse events
EP2627317A4 (en) * 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012085586A1 (en) 2010-12-23 2012-06-28 Shire, Llc Mexiletine prodrugs
HUE026715T2 (en) 2011-01-20 2016-07-28 Bionevia Pharmaceuticals Inc Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use
US9499462B2 (en) 2011-02-02 2016-11-22 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
WO2012112440A2 (en) 2011-02-14 2012-08-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fluorescent potassium ion sensors
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
ES2569252T3 (es) 2011-02-18 2016-05-09 Alexion Pharma International Sàrl Métodos para sintetizar derivados Z del precursor de molibdopterina
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN103930110A (zh) 2011-07-07 2014-07-16 艾科尔公司 吡咯并喹啉基-吡咯烷-2,5-二酮制剂及制备和使用所述制剂的方法
JP2014521725A (ja) 2011-08-10 2014-08-28 ノバルティス・ファルマ・アクチェンゲゼルシャフト ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
RS61761B1 (sr) 2011-09-02 2021-05-31 Incyte Holdings Corp Heterociklilamini kao inhibitori pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6073545B2 (ja) * 2011-10-04 2017-02-01 横浜油脂工業株式会社 リグナン類含有微粒子及び組成物
TW201321371A (zh) 2011-10-14 2013-06-01 Incyte Corp 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
ES2832497T3 (es) 2012-06-13 2021-06-10 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014036242A2 (en) 2012-08-29 2014-03-06 Mount Sinai School Of Medicine Benzothiazole or benzoxazole compounds as sumo activators
US9464093B2 (en) 2012-10-12 2016-10-11 Mayo Foundation For Medical Education And Research Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
NZ707495A (en) 2012-11-01 2019-01-25 Incyte Holdings Corp Tricyclic fused thiophene derivatives as jak inhibitors
WO2014078486A1 (en) 2012-11-15 2014-05-22 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
BR112015016793B1 (pt) 2013-01-15 2021-12-28 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
CN105121023B (zh) * 2013-02-28 2017-08-25 太阳化学公司 用于在液体分散液中制造研磨的固体的装置和连续方法
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
PL2964650T3 (pl) 2013-03-06 2019-06-28 Incyte Holdings Corporation Sposoby i związki pośrednie dla wytwarzania inhibitora jak
EP2968331B1 (en) 2013-03-14 2020-07-01 Icahn School of Medicine at Mount Sinai Pyrimidine compounds as kinase inhibitors
UA119848C2 (uk) 2013-03-15 2019-08-27 Інсайт Холдинґс Корпорейшн Трициклічні гетероцикли як інгібітори білків бет
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
LT3231801T (lt) 2013-05-17 2019-08-12 Incyte Corporation Bipirazolo druska, kaip jak slopiklis
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR102419714B1 (ko) 2013-08-07 2022-07-13 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
LT3066085T (lt) 2013-11-08 2020-06-25 Incyte Holdings Corporation Indolamino 2,3-dioksigenazės inhibitoriaus sintezės būdas
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081246A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10758569B2 (en) 2014-01-13 2020-09-01 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
JP6517827B2 (ja) 2014-01-31 2019-05-22 コグニション セラピューティクス，インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PE20161388A1 (es) 2014-02-28 2016-12-28 Incyte Corp Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
US10064866B2 (en) 2014-04-08 2018-09-04 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
ME03763B (me) 2014-04-23 2021-04-20 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina
JP2017514832A (ja) 2014-04-30 2017-06-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１抑制剤を調製する方法及びその新しい形態
TW201625641A (zh) 2014-05-22 2016-07-16 健臻公司 Ｎａｍｐｔ抑制劑及方法
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US20170114019A1 (en) 2014-06-04 2017-04-27 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
RU2562219C1 (ru) * 2014-06-30 2015-09-10 Закрытое акционерное общество "Путь 910" Способ получения активированной суспензии
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
CN112675178A (zh) 2014-12-22 2021-04-20 速达制药有限公司 预防和治疗血小板增多的癌症患者中的转移性疾病
CA2972668A1 (en) 2014-12-29 2016-07-07 Recordati Ireland Limited Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
SMT202100015T1 (it) 2015-02-27 2021-03-15 Incyte Corp Sali di nibitore di pi3k e preocessi per la loro preparazione
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
MX2017015699A (es) * 2015-06-05 2018-12-11 Lupin Ltd Composiciones de acido diclofenaco.
RS66537B1 (sr) 2015-08-12 2025-03-31 Incyte Holdings Corp Soli inhibitora lsd1
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017053706A1 (en) 2015-09-23 2017-03-30 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SMT202000694T1 (it) 2015-12-22 2021-03-15 Incyte Corp Composti eterociclici come immunomodulatori
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
WO2017141104A2 (en) 2016-02-18 2017-08-24 Immune Therapeutics, Inc. Method for inducing a sustained immune response
KR102744951B1 (ko) 2016-03-28 2024-12-23 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP4137489A1 (en) 2016-06-20 2023-02-22 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180055835A1 (en) 2016-08-25 2018-03-01 Immune Therapeutics Inc. Method for Treating And Preventing Protozoal Infections
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI867311B (zh) 2016-09-09 2024-12-21 美商英塞特公司 吡唑并吡啶化合物及其用途
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3558990T3 (da) 2016-12-22 2022-09-12 Incyte Corp Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
MX388366B (es) 2017-05-15 2025-03-19 Cognition Therapeutics Inc Composiciones para tratar enfermedades neurodegenerativas.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111094269A (zh) 2017-06-29 2020-05-01 瑞蔻达蒂化学制药公司 杂环亚甲基衍生物及其作为mGluR5受体调节剂的用途
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
TWI851542B (zh) 2017-09-11 2024-08-11 美商克魯松藥物公司 Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
JOP20200081A1 (ar) 2017-09-27 2020-04-30 Incyte Corp أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
JP7230041B2 (ja) 2017-10-26 2023-02-28 ザイノミック・ファーマシューティカルズ・インコーポレイテッド Ｂ－ｒａｆキナーゼ阻害物質の結晶塩
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
BR112020011614A2 (pt) * 2017-12-14 2020-12-08 SpecGx LLC Processo de moagem de uma etapa para preparar ésteres de paliperidona micronizada
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
MX2020007869A (es) 2018-01-26 2021-01-08 Recordati Ind Chimica E Farmaceutica S P A Derivados de piperazina condensados con triazol, imidazol y pirrol y su uso como moduladores de receptores mglu5.
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SG11202007805SA (en) 2018-02-16 2020-09-29 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
CR20200421A (es) 2018-02-20 2021-01-26 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
MA52422A (fr) 2018-02-27 2021-01-06 Incyte Corp Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
SG11202008560VA (en) 2018-03-08 2020-10-29 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MA64121B1 (fr) 2018-03-30 2025-04-30 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
SI4219492T1 (sl) 2018-05-11 2025-04-30 Incyte Corporation Heterociklične spojine kot imunomodulatorji
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3802534B1 (en) 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
CN113164398B (zh) 2018-06-29 2023-11-03 因赛特公司 Axl/mer抑制剂的制剂
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
MA53097A (fr) 2018-07-05 2021-05-12 Incyte Corp Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
GB2575490A (en) 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
IL282643B2 (en) 2018-10-31 2025-08-01 Incyte Corp A selective jak1 inhibitor for use in a method of treating hematological disease
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
JP7624922B2 (ja) 2018-12-19 2025-01-31 インサイト・コーポレイション 胃腸疾患の治療のためのｊａｋ１経路阻害剤
CR20210336A (es) 2018-12-20 2021-12-06 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
MX2021010545A (es) 2019-03-05 2021-11-17 Incyte Corp Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US12187722B2 (en) 2019-03-15 2025-01-07 The General Hospital Corporation Small molecule inhibitors of TEAD transcription factors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114450276A (zh) 2019-08-06 2022-05-06 因赛特公司 Hpk1抑制剂的固体形式
EP4009969A1 (en) 2019-08-08 2022-06-15 Laekna Limited Method of treating cancer
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
PH12022550470A1 (en) 2019-08-26 2023-02-27 Incyte Corp Triazolopyrimidines as a2a / a2b inhibitors
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4041731A1 (en) 2019-10-11 2022-08-17 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
TW202120504A (zh) 2019-11-11 2021-06-01 美商英塞特公司 Pd-1/pd-l1 抑制劑之鹽及結晶型
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
KR20220150281A (ko) 2020-01-03 2022-11-10 인사이트 코포레이션 A2a/a2b 및 pd-1/pd-l1 억제제를 포함하는 조합 요법
US20210269434A1 (en) 2020-01-10 2021-09-02 Incyte Corporation Tricyclic compounds as inhibitors of kras
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
WO2021158891A1 (en) 2020-02-06 2021-08-12 Incyte Corporation Salts and solid forms and processes of preparing a pi3k inhibitor
KR20230017165A (ko) 2020-03-06 2023-02-03 인사이트 코포레이션 Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
WO2021198962A1 (en) 2020-04-01 2021-10-07 Cytocom Inc. Method for treating viral diseases
AU2021254794A1 (en) 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
GB202008135D0 (en) 2020-05-29 2020-07-15 Neolife Int Llc Dietary supplements
PH12022553277A1 (en) 2020-06-02 2024-02-19 Incyte Corp Processes of preparing a jak1 inhibitor
CN115835868A (zh) 2020-06-03 2023-03-21 因赛特公司 用于治疗骨髓增生性赘生物的鲁索利替尼与incb057643的组合
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3184811A1 (en) 2020-06-12 2021-12-16 Incyte Corporation Imidazopyridazine compounds with activity as alk2 inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
US20220241411A1 (en) 2020-11-30 2022-08-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
JP2023552452A (ja) 2020-12-08 2023-12-15 インサイト・コーポレイション 白斑治療用のｊａｋ１経路阻害薬
WO2022133176A1 (en) 2020-12-18 2022-06-23 Incyte Corporation Oral formulation for a pd-l1 inhibitor
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4271384A1 (en) 2020-12-29 2023-11-08 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
GB202103100D0 (en) 2021-03-05 2021-04-21 Suda Pharmaceuticals Ltd Mitigating the off-target pharmacology of anagrelide in the treatment of thrombocytosis in various diseases
US12077539B2 (en) 2021-03-22 2024-09-03 Incyte Corporation Imidazole and triazole KRAS inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
IL308216A (en) 2021-05-03 2024-01-01 Incyte Corp Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN117500504A (zh) 2021-05-03 2024-02-02 因赛特公司 用于治疗结节性痒疹的鲁索替尼
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN117616015A (zh) 2021-07-02 2024-02-27 歌礼生物科技（杭州）有限公司 作为pd-l1相互作用的免疫调节剂的杂环化合物
EP4367117A1 (en) 2021-07-07 2024-05-15 Incyte Corporation Tricyclic compounds as inhibitors of kras
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
EP4387974A1 (en) 2021-08-17 2024-06-26 Ascletics Bioscience Co., Ltd. Compounds as immunomodulators of pd-l1 interactions
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CN113908932A (zh) * 2021-09-22 2022-01-11 浙江工业大学 一种磁性粉体连续细化及级分的方法与装置
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
JP2024539651A (ja) 2021-10-14 2024-10-29 インサイト・コーポレイション Ｋｒａｓの阻害剤としてのキノリン化合物
US20230203010A1 (en) 2021-12-03 2023-06-29 Incyte Corporation Bicyclic amine cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
EP4452982A1 (en) 2021-12-22 2024-10-30 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
CN114289159B (zh) * 2021-12-29 2023-06-06 湖北华世通生物医药科技有限公司 碳酸司维拉姆的后处理方法及其制备方法
CR20240408A (es) 2022-03-07 2024-11-22 Incyte Corp Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
CN119013022A (zh) 2022-03-14 2024-11-22 来凯有限公司 癌症的组合治疗
MX2024011378A (es) 2022-03-17 2024-09-23 Incyte Corp Compuestos de urea triciclica como inhibidores de la variante v617f de la cinasa de janus 2 (jak2).
CR20250008A (es) 2022-06-08 2025-05-05 Incyte Corp Compuestos tricíclicos de triazolo como inhibidores de dgk
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
US20240058343A1 (en) 2022-08-05 2024-02-22 Incyte Corporation Treatment of urticaria using jak inhibitors
TW202416968A (zh) 2022-10-21 2024-05-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
WO2024108100A1 (en) 2022-11-18 2024-05-23 Incyte Corporation Heteroaryl fluoroalkenes as dgk inhibitors
EP4389746A3 (en) 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
AR131101A1 (es) 2023-01-12 2025-02-19 Incyte Corp Heteroarilfluoroalquenos como inhibidores de dgk
AU2024237095A1 (en) 2023-03-13 2025-09-25 Incyte Corporation Bicyclic ureas as kinase inhibitors
AU2024236890A1 (en) 2023-03-16 2025-09-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
US20240390340A1 (en) 2023-04-18 2024-11-28 Incyte Corporation Pyrrolidine kras inhibitors
US20240368156A1 (en) 2023-04-18 2024-11-07 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
US20250066363A1 (en) 2023-08-24 2025-02-27 Incyte Corporation Bicyclic DGK Inhibitors
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
WO2025096373A1 (en) 2023-11-02 2025-05-08 Incyte Corporation Ruxolitinib for use in the treatment of prurigo nodularis
US20250179083A1 (en) 2023-12-05 2025-06-05 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
US20250186450A1 (en) 2023-12-06 2025-06-12 Incyte Corporation COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600528A1 (en) * 1992-11-25 1994-06-08 NanoSystems L.L.C. Method of grinding pharmaceutical substances

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076347A (en) * 1976-07-21 1978-02-28 Dayco Corporation Antifriction nylon member
US4547534A (en) * 1983-03-18 1985-10-15 Memorex Corporation Method to disperse fine solids without size reduction
US4768366A (en) * 1987-04-30 1988-09-06 Tadeusz Sendzimir Wide strip mill using pressure elements
GB9726543D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel compositions
EP1185371B2 (en) * 1999-06-01 2008-11-12 Elan Pharma International Limited Small-scale mill and method thereof
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600528A1 (en) * 1992-11-25 1994-06-08 NanoSystems L.L.C. Method of grinding pharmaceutical substances

Also Published As

Publication number Publication date
NO20026120D0 (no) 2002-12-19
NZ522783A (en) 2004-07-30
KR100786927B1 (ko) 2007-12-17
PT1294358E (pt) 2004-12-31
AR029284A1 (es) 2003-06-18
TWI290836B (en) 2007-12-11
CZ20024263A3 (cs) 2003-06-18
DE60105023D1 (de) 2004-09-23
IL153231A0 (en) 2003-07-06
AU1560802A (en) 2002-01-08
AU2002215608B2 (en) 2004-12-09
US20040089753A1 (en) 2004-05-13
JP4188078B2 (ja) 2008-11-26
ATE273695T1 (de) 2004-09-15
JP2004501182A (ja) 2004-01-15
CA2413330A1 (en) 2002-01-03
DE60105023T2 (de) 2005-08-18
ES2225624T3 (es) 2005-03-16
NO20026120L (no) 2003-01-27
MXPA03000051A (es) 2003-08-19
EP1294358A2 (en) 2003-03-26
US20060214037A1 (en) 2006-09-28
HU230396B1 (hu) 2016-04-28
CZ303572B6 (cs) 2012-12-12
EP1294358B1 (en) 2004-08-18
MY128806A (en) 2007-02-28
KR20030018013A (ko) 2003-03-04
WO2002000196A3 (en) 2002-06-27
SI1294358T1 (en) 2004-12-31
NO333747B1 (no) 2013-09-09
IL153231A (en) 2008-06-05
WO2002000196A2 (en) 2002-01-03
BR0111747A (pt) 2003-07-08
PL202623B1 (pl) 2009-07-31
HK1055242A1 (en) 2004-01-02
HUP0301583A2 (en) 2003-08-28
PL359065A1 (pl) 2004-08-23
CN1438876A (zh) 2003-08-27

Similar Documents

Publication Publication Date Title
CN1321628C (zh) 湿磨方法
AU2002215608A1 (en) Wet milling process
CN100457090C (zh) 磨制颗粒
JP5529884B2 (ja) 微粉末の製造方法及び同方法で製造された微粉末
Paredes et al. Ricobendazole nanocrystals obtained by media milling and spray drying: pharmacokinetic comparison with the micronized form of the drug
AU2003295704B2 (en) Methods and apparatus for making particles using spray dryer and in-line jet mill
EP1401401B1 (en) Method for high through put screening using a small scale mill or microfluidics
JP2010047579A (ja) セルロース系表面安定剤を用いたヒト免疫不全ウイルス（ｈｉｖ）プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法
KR20080110807A (ko) 마이크로 분쇄 및 마이크로-시드상의 결정화에 의한 결정성유기 미세입자 조성물의 생성 방법과 장치 및 이의 용도
TW200826973A (en) Method of micronization
HK1055242B (en) Wet milling process
Papdiwal et al. Formulation and characterization of nateglinide nanosuspension by precipitation method
WO2002094223A2 (en) Formulation containing halofantrine hydrochloride
EP4069202A1 (en) Deposition of nanosuspensions of active pharmaceutical ingredients on carriers
Pillai Development and Characterization of Solid Dosage form Incorporating Camptothecin Analog Nanoparticles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070620

Termination date: 20190622